Loading clinical trials...
Loading clinical trials...
FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer
Conditions
Interventions
dalteparin
quality-of-life assessment
Locations
60
United Kingdom
Stoke Mandeville Hospital
Aylesbury-Buckinghamshire, England, United Kingdom
Furness General Hospital
Barrow in Furness, England, United Kingdom
Royal Blackburn Hospital
Blackburn, England, United Kingdom
Blackpool Victoria Hospital
Blackpool, England, United Kingdom
Royal Bournemouth Hospital
Bournemouth, England, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom
Start Date
August 1, 2007
Primary Completion Date
August 1, 2012
Last Updated
August 8, 2011
NCT05198830
NCT06498635
NCT06066138
NCT05692635
NCT07336732
NCT07190248
Lead Sponsor
Velindre NHS Trust
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions